PMC:7346000 / 2647-3891 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T36","span":{"begin":64,"end":73},"obj":"Disease"},{"id":"T37","span":{"begin":106,"end":141},"obj":"Disease"},{"id":"T38","span":{"begin":112,"end":141},"obj":"Disease"},{"id":"T39","span":{"begin":143,"end":147},"obj":"Disease"},{"id":"T40","span":{"begin":328,"end":337},"obj":"Disease"},{"id":"T41","span":{"begin":458,"end":466},"obj":"Disease"},{"id":"T42","span":{"begin":583,"end":591},"obj":"Disease"},{"id":"T43","span":{"begin":626,"end":630},"obj":"Disease"},{"id":"T44","span":{"begin":681,"end":691},"obj":"Disease"},{"id":"T45","span":{"begin":769,"end":779},"obj":"Disease"},{"id":"T46","span":{"begin":825,"end":835},"obj":"Disease"},{"id":"T47","span":{"begin":879,"end":888},"obj":"Disease"},{"id":"T48","span":{"begin":1009,"end":1017},"obj":"Disease"},{"id":"T49","span":{"begin":1084,"end":1092},"obj":"Disease"},{"id":"T50","span":{"begin":1114,"end":1127},"obj":"Disease"},{"id":"T51","span":{"begin":1129,"end":1133},"obj":"Disease"}],"attributes":[{"id":"A36","pred":"mondo_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A37","pred":"mondo_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A38","pred":"mondo_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/MONDO_0009971"},{"id":"A39","pred":"mondo_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A40","pred":"mondo_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A41","pred":"mondo_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A42","pred":"mondo_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A43","pred":"mondo_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A44","pred":"mondo_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A45","pred":"mondo_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A46","pred":"mondo_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A47","pred":"mondo_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A48","pred":"mondo_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A49","pred":"mondo_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A50","pred":"mondo_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"},{"id":"A51","pred":"mondo_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/MONDO_0007163"}],"text":"Recently, it has been reported that a relatively high number of influenza patients presenting with severe acute respiratory distress syndrome (ARDS) also rapidly develop IPA, which is associated with increased duration of hospitalization and mortality [4,5]. Corticosteroid use and pulmonary epithelial damages caused by severe influenza are the main risk factors for developing IPA [4,5]. The recent global pandemic of coronavirus disease-19, also known as COVID-19, has infected over 6 million patients worldwide, with more than 360,000 deaths. It has been shown that up to 40% of COVID-19 hospitalized patients can develop ARDS [6], and thereby become susceptible to acquire co-infections caused by bacteria and also Aspergillus spp. [7,8], although frequency of co-infections seems to vary between centers and overall co-infections may occur less frequently than with severe influenza [9]. Once they occur, these superinfections are associated with high mortality rates and may prolong the acute phase of COVID-19 [10]. In this comprehensive review, we discuss various aspects of COVID-19 associated pulmonary aspergillosis (CAPA), focusing specifically on immunology, risk factors, prevalence, diagnosis, treatment, and current challenges."}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T15","span":{"begin":13,"end":16},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T16","span":{"begin":36,"end":37},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T17","span":{"begin":292,"end":302},"obj":"http://purl.obolibrary.org/obo/CL_0000066"},{"id":"T18","span":{"begin":468,"end":471},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T19","span":{"begin":550,"end":553},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T20","span":{"begin":702,"end":710},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_2"},{"id":"T21","span":{"begin":1136,"end":1144},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"}],"text":"Recently, it has been reported that a relatively high number of influenza patients presenting with severe acute respiratory distress syndrome (ARDS) also rapidly develop IPA, which is associated with increased duration of hospitalization and mortality [4,5]. Corticosteroid use and pulmonary epithelial damages caused by severe influenza are the main risk factors for developing IPA [4,5]. The recent global pandemic of coronavirus disease-19, also known as COVID-19, has infected over 6 million patients worldwide, with more than 360,000 deaths. It has been shown that up to 40% of COVID-19 hospitalized patients can develop ARDS [6], and thereby become susceptible to acquire co-infections caused by bacteria and also Aspergillus spp. [7,8], although frequency of co-infections seems to vary between centers and overall co-infections may occur less frequently than with severe influenza [9]. Once they occur, these superinfections are associated with high mortality rates and may prolong the acute phase of COVID-19 [10]. In this comprehensive review, we discuss various aspects of COVID-19 associated pulmonary aspergillosis (CAPA), focusing specifically on immunology, risk factors, prevalence, diagnosis, treatment, and current challenges."}

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T16","span":{"begin":170,"end":173},"obj":"Chemical"},{"id":"T18","span":{"begin":379,"end":382},"obj":"Chemical"}],"attributes":[{"id":"A16","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A17","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"},{"id":"A18","pred":"chebi_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A19","pred":"chebi_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"}],"text":"Recently, it has been reported that a relatively high number of influenza patients presenting with severe acute respiratory distress syndrome (ARDS) also rapidly develop IPA, which is associated with increased duration of hospitalization and mortality [4,5]. Corticosteroid use and pulmonary epithelial damages caused by severe influenza are the main risk factors for developing IPA [4,5]. The recent global pandemic of coronavirus disease-19, also known as COVID-19, has infected over 6 million patients worldwide, with more than 360,000 deaths. It has been shown that up to 40% of COVID-19 hospitalized patients can develop ARDS [6], and thereby become susceptible to acquire co-infections caused by bacteria and also Aspergillus spp. [7,8], although frequency of co-infections seems to vary between centers and overall co-infections may occur less frequently than with severe influenza [9]. Once they occur, these superinfections are associated with high mortality rates and may prolong the acute phase of COVID-19 [10]. In this comprehensive review, we discuss various aspects of COVID-19 associated pulmonary aspergillosis (CAPA), focusing specifically on immunology, risk factors, prevalence, diagnosis, treatment, and current challenges."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T10","span":{"begin":112,"end":132},"obj":"Phenotype"},{"id":"T11","span":{"begin":170,"end":173},"obj":"Phenotype"},{"id":"T12","span":{"begin":379,"end":382},"obj":"Phenotype"}],"attributes":[{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0002098"},{"id":"A11","pred":"hp_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/HP_0020103"},{"id":"A12","pred":"hp_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/HP_0020103"}],"text":"Recently, it has been reported that a relatively high number of influenza patients presenting with severe acute respiratory distress syndrome (ARDS) also rapidly develop IPA, which is associated with increased duration of hospitalization and mortality [4,5]. Corticosteroid use and pulmonary epithelial damages caused by severe influenza are the main risk factors for developing IPA [4,5]. The recent global pandemic of coronavirus disease-19, also known as COVID-19, has infected over 6 million patients worldwide, with more than 360,000 deaths. It has been shown that up to 40% of COVID-19 hospitalized patients can develop ARDS [6], and thereby become susceptible to acquire co-infections caused by bacteria and also Aspergillus spp. [7,8], although frequency of co-infections seems to vary between centers and overall co-infections may occur less frequently than with severe influenza [9]. Once they occur, these superinfections are associated with high mortality rates and may prolong the acute phase of COVID-19 [10]. In this comprehensive review, we discuss various aspects of COVID-19 associated pulmonary aspergillosis (CAPA), focusing specifically on immunology, risk factors, prevalence, diagnosis, treatment, and current challenges."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T15","span":{"begin":0,"end":258},"obj":"Sentence"},{"id":"T16","span":{"begin":259,"end":389},"obj":"Sentence"},{"id":"T17","span":{"begin":390,"end":546},"obj":"Sentence"},{"id":"T18","span":{"begin":547,"end":893},"obj":"Sentence"},{"id":"T19","span":{"begin":894,"end":1023},"obj":"Sentence"},{"id":"T20","span":{"begin":1024,"end":1244},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Recently, it has been reported that a relatively high number of influenza patients presenting with severe acute respiratory distress syndrome (ARDS) also rapidly develop IPA, which is associated with increased duration of hospitalization and mortality [4,5]. Corticosteroid use and pulmonary epithelial damages caused by severe influenza are the main risk factors for developing IPA [4,5]. The recent global pandemic of coronavirus disease-19, also known as COVID-19, has infected over 6 million patients worldwide, with more than 360,000 deaths. It has been shown that up to 40% of COVID-19 hospitalized patients can develop ARDS [6], and thereby become susceptible to acquire co-infections caused by bacteria and also Aspergillus spp. [7,8], although frequency of co-infections seems to vary between centers and overall co-infections may occur less frequently than with severe influenza [9]. Once they occur, these superinfections are associated with high mortality rates and may prolong the acute phase of COVID-19 [10]. In this comprehensive review, we discuss various aspects of COVID-19 associated pulmonary aspergillosis (CAPA), focusing specifically on immunology, risk factors, prevalence, diagnosis, treatment, and current challenges."}

2_test

{"project":"2_test","denotations":[{"id":"32599813-30076119-60095062","span":{"begin":253,"end":254},"obj":"30076119"},{"id":"32599813-22895826-60095063","span":{"begin":255,"end":256},"obj":"22895826"},{"id":"32599813-30076119-60095064","span":{"begin":384,"end":385},"obj":"30076119"},{"id":"32599813-22895826-60095065","span":{"begin":386,"end":387},"obj":"22895826"}],"text":"Recently, it has been reported that a relatively high number of influenza patients presenting with severe acute respiratory distress syndrome (ARDS) also rapidly develop IPA, which is associated with increased duration of hospitalization and mortality [4,5]. Corticosteroid use and pulmonary epithelial damages caused by severe influenza are the main risk factors for developing IPA [4,5]. The recent global pandemic of coronavirus disease-19, also known as COVID-19, has infected over 6 million patients worldwide, with more than 360,000 deaths. It has been shown that up to 40% of COVID-19 hospitalized patients can develop ARDS [6], and thereby become susceptible to acquire co-infections caused by bacteria and also Aspergillus spp. [7,8], although frequency of co-infections seems to vary between centers and overall co-infections may occur less frequently than with severe influenza [9]. Once they occur, these superinfections are associated with high mortality rates and may prolong the acute phase of COVID-19 [10]. In this comprehensive review, we discuss various aspects of COVID-19 associated pulmonary aspergillosis (CAPA), focusing specifically on immunology, risk factors, prevalence, diagnosis, treatment, and current challenges."}